Change in Health-Related Quality of Life in Youth with Chronic Hepatitis B Living in North America: A 5-Year Cohort Study
- PMID: 37756340
- PMCID: PMC12462827
- DOI: 10.1097/MPG.0000000000003957
Change in Health-Related Quality of Life in Youth with Chronic Hepatitis B Living in North America: A 5-Year Cohort Study
Abstract
Background: Greater hepatitis-related symptomology is associated with lower health-related quality-of-life (HRQoL) among untreated youth with chronic hepatitis B (CHB). How HRQoL changes over time in this population is unknown.
Methods: Children from 7 hepatology centers in North America positive for hepatitis B surface antigen, not taking anti-viral therapy, were enrolled in the Hepatitis B Research Network. A validated self-report HRQoL measure, the Child Health Questionnaire Child Report (CHQ-CF87), was completed annually by participants 10-17 years, with demographic variables, liver disease symptoms, and laboratory tests. Linear mixed-effects models were used to evaluate the 10 CHQ-CF87 subscale scores over 5 years among participants who completed the CHQ-CF87 at least twice.
Results: Participants (N = 174) completed the CHQ-CF87 a median of 4 times. Median age was 12 years (interquartile range: 10-14) at baseline; 60% were female, 79% Asian, and 47% adopted. The CHQ-CF87 subscale scores were high at baseline (median range: 75.4-100) and did not differ by time point, except for the Family Activities subscale (mean [95% CI]: 82.3 [79.8-84.8] at baseline; 90.8 [86.1-94.6] week 240). Most subscale scores lacked sufficient individual-level variability in change over time to evaluate predictors. Being White versus Asian predicted a more favorable change in Behavior (6.5 [95% CI: 2.0-11.0]). Older age predicted less favorable change in Mental Health (-0.8 [95% CI: -1.36 to -0.23] per year). Changes in liver enzymes and hepatitis B antigens, DNA, or symptom count were not related to changes in these subscale scores.
Conclusion: HRQoL was generally good and consistent across 5 years in youth with CHB.
Copyright © 2023 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Conflict of interest statement
Dr Schwarzenberg consults for Mirum, Renexxion, and UpToDate; Dr Schwarz has research and consulting funds from Gilead, research funding from Albireo, consulting for Mirum, Sarepta, and UpToDate, and is on the editorial board of JPGN Reports ; Dr Rosenthal has research support from AbbVie, Albireo, Arrowhead, Gilead, Merck, Mirum, Takeda, Travere, and is a consultant for Albireo, Audentes, BioMarin, Dicerna, Encoded, Gilead, MedinCell, Mirum, RNAV8, Takeda, Taysha, and Travere; Dr Murray consults and is on the DSMB of Albireo and Gilead and the Board of Director of Improve Care Now; Dr Mogul is Senior Director for Scientific Affairs and Engagement for Mirum, Inc. Dr Ling has research support from AbbVie. The remaining authors report no conflicts of interest.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
